M

Mersana Therapeutics
D

MRSN

0.37200
USD
0.01
(2.45%)
مغلق
حجم التداول
25,037
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
46,362,858
أصول ذات صلة
AMGN
AMGN
-2.10
(-0.70%)
295.22 USD
C
CRSP
0.050
(0.12%)
41.360 USD
E
EDIT
-0.20500
(-9.45%)
1.96500 USD
INCY
INCY
-1.490
(-2.15%)
67.750 USD
N
NKTR
-0.21000
(-2.40%)
8.54000 USD
REGN
REGN
7.50
(1.44%)
529.39 USD
المزيد
الأخبار المقالات

العنوان: Mersana Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADCplatforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.